Acucela Receives Orphan Designation From the EMA for Emixustat for the Treatment of Stargardt Disease

120

SEATTLE–(BUSINESS WIRE)–Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the European Medicines Agency (EMA) granted orphan designation to Acucela’s leading drug candidate emixustat hydrochloride (“emixustat”) for the treatment of Stargardt disease. The orphan designation does not apply to other indications for which emixustat is being developed. To receive an orphan desi….

 

http://www.businesswire.com/news/home/20190609005040/en/Acucela-Receives-Orphan-Designation-EMA-Emixustat-Treatment/